Drug Eluting Stent (DES) Market Size, Share, Future Analysis, 2026-2034

Market Overview

According to fortune business insights, the global drug eluting stent market size was valued at USD 6.94 billion in 2025. The market is projected to grow from USD 7.59 billion in 2026 to USD 15.52 billion by 2034, exhibiting a CAGR of 9.35% during the forecast period. North America dominated the drug eluting stent market with a market share of 30.82% in 2025.

The analysis shows that the introduction of technologically advanced stents by key market players is anticipated to limit the risk of early and late thrombosis. For example, in February 2019, Biotronik received FDA approval for Orsiro, the first ultrathin, bioresorbable polymer-coated Drug Eluting Stent (DES). This trend indicates strong demand and continuous innovation in the drug eluting stent market worldwide.

Major Players Profiled in the Market Report:

• Boston Scientific Corporation

• Abbott

• Medtronic

• Biotronik

• Terumo Corporation

• MicroPort Scientific Corporation

• Sahajanand Medical Technologies

• Others

Segments

Rising Incidence of Coronary Artery Disease to Propel Coronary Stenting Segment GrowthBased on indication, the market is segmented into coronary stenting and peripheral stenting. The coronary stenting segment holds the largest market share and dominates the market owing to the growing prevalence of coronary artery diseases and a strong preference for Drug Eluting Stents by healthcare providers globally.

High Clinical Effectiveness to Drive Sirolimus Segment ExpansionBy drug, the market is categorized into Sirolimus, Paclitaxel, Zotarolimus, Everolimus, & Others. The sirolimus segment is leading the market as there is high preference among end-users for its distinct qualities, which include limited or reduced late lumen loss and angiographic restenosis compared to other options.

Flexibility and Biocompatibility to Dominate Cobalt-Chromium SegmentBased on scaffold, the market is segmented into cobalt-chromium, platinum-chromium, nitinol, and others. The cobalt-chromium segment holds the largest market share owing to the increased use of these stents, which offer flexibility, a long shelf-life, and better biocompatibility, driving high demand.

Higher Adoption in Hospitals to Dominate the MarketBased on end-user, the market is segmented into hospitals, specialty clinics, and others. The hospital segment holds the largest market share owing to rising healthcare expenditure, the development of new hospitals in developing nations, and an increasing number of coronary intervention procedures being performed in hospital settings.

Drivers & Restraints

Growing Prevalence of Cardiovascular Disease to Propel Market GrowthThe rapid growth in cardiovascular diseases (CVDs) globally, driven by factors like smoking, diabetes, and lifestyle changes, has raised the demand for drug eluting stents. The rising prevalence of both coronary artery disease (CAD) and peripheral arterial disease (PAD), especially in regions like the U.S. and Europe, is boosting the drug eluting stent market growth.

However, frequent product recalls by key market players may hamper market growth. For instance, some recalls have been initiated due to issues with partial stent deployment, which can result in vessel trauma and prolong implant procedures, potentially impacting market confidence.

For detailed market insights: https://www.fortunebusinessinsights.com/drug-eluting-stent-des-market-102612

Regional Insights

Favorable Reimbursement Policies in the U.S. Propel Market Growth in North AmericaNorth America holds the dominant drug eluting stent market share and is projected to experience growth during the forecast period. The region’s growth is attributed to favorable reimbursement policies, the high prevalence of cardiovascular diseases, and the rapid adoption of advanced stent technologies, including biodegradable polymer-based scaffolds.

Asia Pacific is one of the fastest-growing regions in the market. The growth is attributed to the increasing prevalence of cardiovascular diseases and the introduction of technologically advanced drug eluting stents in developing nations such as China and Japan.

Drug Eluting Stent Market Future Growth:

The drug eluting stent market is experiencing robust growth, fueled by the rising prevalence of cardiovascular diseases and rapid technological advancements. Today's market is increasingly drawn to next-generation stents with bioabsorbable polymers, which aim to avoid restenosis, ensure patient safety, and improve clinical outcomes by gradually being absorbed by the body. Additionally, there is a focus on ultrathin stent designs to minimize tissue damage and accelerate healing. The rapid adoption of these advanced technologies and strong R&D by major players are key growth drivers. While North America dominates, the Asia-Pacific region is seeing a surge in demand, driven by an increasing disease burden and growing healthcare infrastructure.

Competitive Landscape

Growing Adoption of Innovation and Geographic Expansion Strategies to Propel Market GrowthThe market features prominent players like Abbott, Medtronic, and Boston Scientific Corporation, which together hold a significant market share. These leading companies are accelerating growth through strategic initiatives such as robust research and development, investment in clinical trials, seeking regulatory approvals for innovative products, and strategic geographic expansion to meet global demand.

Key Industry Development

• June 2021: Abbott announced that its XIENCE stent line received U.S. FDA and CE Mark approval for a one-month Dual Antiplatelet Therapy (DAPT), the shortest blood thinning course for patients with a high bleeding risk.